Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder

NCT07303049 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-01
Last updated
2025-12-24

Condition(s) studied

Complex Neurodevelopmental Disorder

Investigational drug(s) / intervention(s)

Intensive rhythmic musical training

Intensive rhythmic musical training: Participants undergo an intensive rhythmic training program using percussion instruments. The program takes place over one week, with daily sessions focused on rhythmic exercises. It focuses on developing motor coordination, timing, and cognitive skills through group-based rhythmic exercises and activities. Sessions include guided percussion practice designed to improve sensorimotor integration and enhance cognitive-motor performance.

Study summary

In the wide range of studies carried out on neurodevelopmental disorders (NDD), rhythm disorders have been identified as a major cross-cutting component. The aim of our research is to evaluate the effect of intensive rhythm-based rehabilitation on rhythmic abilities and its generalization to attentional, executive and reading skills.

Eligibility

Sex
ALL
Min age
8 Years
Max age
126 Months
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of neurodevelopmental disorder involving at least two impairments (ADHD + DCD, ADHD + Dyslexia, Dyslexia + DCD, ADHD + Dyslexia + DCD), according to DSM-5 criteria (2015), established at the Language and Learning Disorders Reference Center (CRTLA) of Toulouse University Hospital. * Aged between 8 years and 10 years 6 months. * Enrolled in elementary school. * Visual, auditory (with permitted aids), motor, oral and written expression and comprehension abilities sufficient, according to the investigator physician's assessment, to perform cognitive tests and follow the intervention. * Patient beneficiary/affiliate of the French Social Security system. * Signed informed consent from parent(s) / legal guardian(s) in accordance with French law and Good Clinical Practice, along with minor's assent. * Authorization for image and sound recording. Exclusion Criteria: * Practice of a musical instrument during the current year (in a music school or leisure activity). * Behavioral disorder making group practice difficult (e.g., oppositional defiant disorder) according to the investigator's opinion. * Patient diagnosed with autism spectrum disorder or intellectual developmental disorder (IQ \< 70). * Patient with epilepsy (with or without treatment). * Uncorrected hearing or visual impairment. * Current treatment with psychostimulants or psychotropic drugs (notably methylphenidate, antidepressants). * Patient lacking access to a stable internet connection required for teleconsultation assessments. * Any family or sociological condition preventing compliance with the procedures outlined in the study protocol, according to the investigator's opinion. * Patient participating in another human research study involving experimental treatment or behavioral therapy. * Ongoing rehabilitative care is not an exclusion criterion for the study.

Primary outcome measure(s)

  • Rhythmic structure reproduction task (Stambak-type test) — From week 2 after enrollment to week 14

Trial sites (1)

FacilityCityRegionStatus
Hôpital Purpan Toulouse Occitanie
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07303049 on ClinicalTrials.gov ↗ ← All trials in France